In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma's Biggest Drug Delivery Experiment: Johnson & Johnson

Executive Summary

J&J has been Big Pharma's most aggressive experimenter with the drug-delivery and formulations world, but its two biggest transactions haven't provided the value J&J had originally hoped for.

You may also be interested in...



Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors

The annual JP Morgan conference has always been a stage for reviewing new solutions to the basic business-model problem of biotechnology. But as Big Pharma's troubles have grown, the conference has also become a showcase for large drug company problems. The quick fix: keep shareholders in the stocks by returning cash to them. Medium term: adopt one of four basic business models. Longer term: disaggregate.

Drug Delivery Heats Up

The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.

Drug Delivery Heats Up

The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel